The Centers for Disease Control and Prevention announced that PrEP among at-risk men increased 500 percent between 2014 to 2017. And those numbers are expected to rise following Gilead Sciences’ new commitment to donate up to 2.4 million bottles of Truvada to the CDC by 2030 (which amounts to 200,000 per year). The study is […]
PrEP Use Up 500 Percent In Just Three Years Read More »
Earlier this month, pharmaceutical company Gilead Sciences announced that it will donate enough HIV prevention drug Truvada to the Centers for Disease Control and Prevention (CDC) to benefit 200,000 people at risk for HIV. While news of the announcement was met positively, it also came ahead of some other negative headlines surrounding the drugmaker, coupled
Drugmaker Gilead Is Making HIV Prevention Meds More Accessible Read More »
There is a generation gap when it comes to knowing and understanding HIV prevention. Young gay and bisexual men and other men who have sex with men (YGBM) in BC are less likely to be aware of some HIV prevention and treatment options compared to older men, according to a recently published BC-CfE study.
Education key to HIV awareness among youth Read More »
When the United Nations Commission on Human Rights declared last year that Venezuela was in “a downward spiral with no end in sight,” Marco Torrealba knew exactly what that meant. A former corporate journalist, Torrealba fled Venezuela in 2015 leaving behind his family, friends, and career. “I grew up in a very poor area in
They Found a Better Way to Get Latinx Miami on PrEP Read More »
The largest treatment-as-prevention study for gay and bisexual men confirms that people on antiretroviral therapy with undetectable viral load do not transmit HIV. Results from the PARTNER2 study, which enrolled nearly 1,000 mixed-status gay male couples in 14 European countries, saw no genetically linked HIV transmissions when the positive partner was on effective treatment. “PARTNER2
Study confirms no transmissions with undetectable HIV Read More »
Thousands of people at the highest risk of acquiring HIV in B.C. are benefiting after a successful year since government expanded coverage for HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). “Since expanding access to PrEP on Jan. 1, 2018, nearly 3,300 people have been prescribed the potentially life-saving medications. It is positive to see
One year of preventing new HIV infections throughout B.C. Read More »
THOUSANDS of people at the highest risk of acquiring HIV in B.C. are benefiting after a successful year since government expanded coverage for HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). “Since expanding access to PrEP on January 1, 2018, nearly 3,300 people have been prescribed the potentially life-saving medications. It is positive to see
One year of preventing new HIV infections throughout B.C. Read More »
ANKORS opened an office in Cranbrook in September of 1999. ANKORS is an acronym for “AIDS Network Resource and Support Services.” The Vision: Individual and community wellness for all. The Mission: ANKORS’ mission is to respond to the evolving needs of those living with and affected by HIV/AIDS, Hepatitis C and other blood borne pathogens:
Testing, treatment and harm reduction Read More »
Premier John Horgan has issued the following statement in recognition of World AIDS Day on Dec. 1, 2018: “2018 marks the 30th anniversary of the first World AIDS Day. On this day in particular, British Columbians wear the red ribbon to acknowledge people living with HIV, remember those we have lost to this disease and
Premier’s statement in recognition of World AIDS Day Read More »
A study recently published in The Journal of Acquired Immune Deficiency Syndromes indicates that transgender (trans) women in Brazil had low levels of pre-exposure prophylaxis (PrEP) awareness. This was combined with significant proportions being willing to use PrEP as a prevention tool and being eligible for PrEP. Another recent qualitative study published in Culture, Health
High levels of unmet PrEP needs among transgender women in Brazil Read More »
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
